Closed Loop Medicine (CLM) is a new breed of therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised regimens. The company is focussed on improving outcomes for patients suffering from chronic disease by creating personalised and integrated treatment pathways enabled by new closed loop models of care. CLM combines proven drugs with digital therapeutics and, where relevant, devices and diagnostics, through a single prescription enabling the digitisation and data capture of an entire care continuum. This provides patients and clinicians with the tools and information they need to truly optimise different treatment options, minimising unwanted side effects and increasing compliance.
IQ Capital first invested in CLM at Seed stage in 2019.